BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK
4969 results:

  • 1. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
    Gou Q; Gou Q; Gan X; Xie Y
    Sci Rep; 2024 May; 14(1):10317. PubMed ID: 38705930
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
    Haderk F; Chou YT; Cech L; Fernández-Méndez C; Yu J; Olivas V; Meraz IM; Barbosa Rabago D; Kerr DL; Gomez C; Allegakoen DV; Guan J; Shah KN; Herrington KA; Gbenedio OM; Nanjo S; Majidi M; Tamaki W; Pourmoghadam YK; Rotow JK; McCoach CE; Riess JW; Gutkind JS; Tang TT; Post L; Huang B; Santisteban P; Goodarzi H; Bandyopadhyay S; Kuo CJ; Roose JP; Wu W; Blakely CM; Roth JA; Bivona TG
    Nat Commun; 2024 May; 15(1):3741. PubMed ID: 38702301
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
    Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
    Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
    Kong Y; Hong L; Xu XC; Chen YF; Xu J
    PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
    Bilgin B; Kuralay Y; Yucel S
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):215. PubMed ID: 38668879
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
    Grant C; Nagasaka M
    Cancer Treat Rev; 2024 May; 126():102724. PubMed ID: 38636443
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce lung cancer Regrowth after Crizotinib Treatment.
    Horvat NK; Chocarro S; Marques O; Bauer TA; Qiu R; Diaz-Jimenez A; Helm B; Chen Y; Sawall S; Sparla R; Su L; Klingmüller U; Barz M; Hentze MW; Sotillo R; Muckenthaler MU
    ACS Nano; 2024 Apr; 18(17):11025-11041. PubMed ID: 38626916
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comparative study of imaging and pathology of primary mucinous adenocarcinoma with different imaging manifestations.
    Han J; Gao J; Chen D; Du M; Wu Y; Ma X; Xie M; Han H; Wu C; Xue X
    Clin Respir J; 2024 Apr; 18(4):e13750. PubMed ID: 38616354
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with alk fusion: a case report and review of the literature.
    Zhang P; Xu J; Wu Q; Qian J; Wang S
    Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or alk Alterations.
    Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
    Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Precision nanomedicine to treat non-small cell lung cancer.
    Dessai A; Nayak UY; Nayak Y
    Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
    Wang T; Zhang L; Cheng Y
    Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [A case of crizotinib-associated renal cysts].
    Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Alectinib in Resected
    Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
    N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
    Tong D; Chisholm J; Madden B; Ahmed M
    J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
    Malapelle U; Passiglia F; Pepe F; Pisapia P; Lucia Reale M; Cortinovis D; Fraggetta F; Galetta D; Garbo E; Graziano P; Pagni F; Pasello G; Piovano P; Pilotto S; Tiseo M; Genova C; Righi L; Troncone G; Novello S
    Lung Cancer; 2024 May; 191():107787. PubMed ID: 38593479
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
    Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
    Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 249.